immune system
• DSS-treated mice exhibit increased survival with reduced weight loss, colon degeneration, loss of epithelium barrier function, and increased cell proliferation in the colon compared with wild-type mice
|
• in MOG35-55 treated mice
|
• in MOG35-55 treated mice
|
• enhanced caspase-1-dependent induced pyroptosis peritoneal exudate macrophages
|
• in MOG35-55 or DSS-treated mice
|
• from peritoneal exudate macrophages stimulated with LPS and nigericin, LPS and ATP, LPS and silica, or dsDNA treatment
• from macrophages of MOG35-55 treated mice
|
• MOG35-55 treated mice exhibit increased EAE clinical score, increased leukocyte spinal cord infiltration, increased TH1 and TH17 cells in the spinal cord and spleen, and increased IL-beta expression form macrophages compared with wild-type mice
|
digestive/alimentary system
• DSS-treated mice exhibit increased cell proliferation in the colon compared with wild-type mice
|
• DSS-treated mice exhibit increased survival with reduced weight loss, colon degeneration, loss of epithelium barrier function, and increased cell proliferation in the colon compared with wild-type mice
|
homeostasis/metabolism
• in MOG35-55 or DSS-treated mice
|
hematopoietic system
• in MOG35-55 treated mice
|
• in MOG35-55 treated mice
|
• enhanced caspase-1-dependent induced pyroptosis peritoneal exudate macrophages
|
cellular
• DSS-treated mice exhibit increased cell proliferation in the colon compared with wild-type mice
|